{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T18:29:47Z","timestamp":1782239387292,"version":"3.54.5"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.cllc.2026.01.009","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T23:30:53Z","timestamp":1769470253000},"page":"140-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["TIGOS Trial: A Randomized, Double-Blind, Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as First-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer"],"prefix":"10.1016","volume":"27","author":[{"given":"Luis G.","family":"Paz-Ares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth John","family":"O'Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishwanath Suresh","family":"Gharpure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Pisupati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misena","family":"Pacius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal E.","family":"Ready","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2026.01.009_bib0001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","article-title":"SCLC: epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection","volume":"18","author":"Wang","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.01.009_bib0002","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/OTT.S272552","article-title":"Extensive-stage small-cell lung cancer: current landscape and future prospects","volume":"16","author":"Saida","year":"2023","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.cllc.2026.01.009_bib0003","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.01.009_bib0004","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2026.01.009_bib0005","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA."},{"key":"10.1016\/j.cllc.2026.01.009_bib0006","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2026.01.009_bib0007","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S1470-2045(25)00480-2","article-title":"Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemoimmunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study","volume":"26","author":"Paulson","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2026.01.009_bib0008","doi-asserted-by":"crossref","first-page":"S1456","DOI":"10.1016\/j.annonc.2025.08.3368","article-title":"2757O Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): deLLphi-303 study","volume":"36","author":"Wermke","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cllc.2026.01.009_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107924","article-title":"Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the phase III IMpower133 study and the phase III IMbrella a extension study","volume":"196","author":"Reck","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2026.01.009_bib0010","article-title":"BMS-986012, an anti-fucosyl-GM1 monoclonal antibody as monotherapy or in combination with nivolumab in relapsed\/refractory SCLC: results from a first-in-human phase 1\/2 study","volume":"3","author":"Chu","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.cllc.2026.01.009_bib0011","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1158\/1078-0432.CCR-18-0018","article-title":"A novel, fully human anti-fucosyl-GM1 antibody demonstrates potent in vitro and in vivo antitumor activity in preclinical models of small cell lung cancer","volume":"24","author":"Ponath","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2026.01.009_bib0012","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.01.009_bib0013","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cllc.2018.12.001","article-title":"A phase II study of nivolumab in patients with advanced non\u2013small-cell lung cancer who responded to prior PD-1\/L1 inhibitors: West Japan Oncology Group 9616L (WJOG9616L)","volume":"20","author":"Akamatsu","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2026.01.009_bib0014","doi-asserted-by":"crossref","first-page":"S1061","DOI":"10.1016\/j.annonc.2024.08.1877","article-title":"BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE\/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): interim analysis (IA) of a randomized phase II study","volume":"35","author":"Kalinka","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2026.01.009_bib0015","series-title":"ESMO Annual Congress","article-title":"BMS-986012 (anti-fucosyl-monosialoganglioside-1) with carboplatin + etoposide + nivolumab as first-line therapy in extensive-stage small cell lung cancer: interim analysis of a randomized phase 2 study","author":"Kalinka","year":"2024"},{"key":"10.1016\/j.cllc.2026.01.009_bib0016","doi-asserted-by":"crossref","first-page":"S1069","DOI":"10.1016\/j.annonc.2024.08.1892","article-title":"Expression analysis of Fuc-GM1 ganglioside in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) with BMS-986012, nivolumab, and carboplatin-etoposide","volume":"35","author":"O'Byrne","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2026.01.009_bib0017","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35938","article-title":"Randomized phase II clinical trial of cisplatin\/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161","volume":"131","author":"Leal","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2026.01.009_bib0018","unstructured":"ClinicalTrials.gov. A study to compare the efficacy and safety of BMS-986489 (BMS-986012+ nivolumab fixed dose combination) in combination with carboplatin plus etoposide to that of atezolizumab with carboplatin plus etoposide as first-line therapy in participants with extensive-stage small cell lung cancer (TIGOS). 2022. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT06646276 Accessed: November 12, 2025."},{"key":"10.1016\/j.cllc.2026.01.009_bib0019","unstructured":"ClinicalTrials.gov. BMS-986489 (atigotatug + nivolumab) vs durvalumab in limited-stage small-cell lung cancer (TIGOS-LS) (TIGOS-LS). 2025. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06773910 Accessed: November 12, 2025."}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:46:41Z","timestamp":1777618001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1525730426000185"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.01.009","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TIGOS Trial: A Randomized, Double-Blind, Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as First-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}